Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
about
Oncolytic viruses as therapeutic cancer vaccinesHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyA dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibitionVirus-mimicking nano-constructs as a contrast agent for near infrared photoacoustic imaging.Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.Tumor-specific delivery of biologics by a novel T-cell line HOZOT.Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Inhibitors of C5 complement enhance vaccinia virus oncolysis.Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusOncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Anti-tumor function of double-promoter regulated adenovirus carrying SEA gene, in the treatment of bladder cancer.The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.Combination of viral oncolysis and tumor-specific immunity to control established tumorsOncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvementVirotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter.Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityPhotodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice.TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Cytotoxic Activity and Antiproliferative Effects of Crude Skin Secretion from Physalaemus nattereri (Anura: Leptodactylidae) on in vitro Melanoma Cells.Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma.Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-ASVirotherapy, gene transfer and immunostimulatory monoclonal antibodies.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virusPotential for enhanced therapeutic activity of biological cancer therapies with doxycycline combinationA rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancerCoronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastomaArmed replicating adenoviruses for cancer virotherapy.
P2860
Q21245758-C8D055C8-B055-409E-A162-49FE2832F9D5Q27021570-A1291B78-8C5E-4CBE-B328-52C522CF7122Q28477181-5B3EB28D-B668-4224-A8FE-62EE1F6C4B48Q30441972-C13D09B1-3C02-4973-BE75-95765756D754Q30620931-2895E71E-BE1E-405B-9742-B1485C78E343Q30830225-FBF069C1-7BB4-4D26-BF90-9D6F7C15A5A3Q33587040-4F3797DF-A77A-496C-BBBA-98136500934AQ33635033-7028EBA4-02E3-47FF-B5B8-CA20C5F20CDEQ33768177-86DF5C9D-72D8-460A-9FFE-E44CEC6EE808Q33769835-499C8904-1B16-455A-82E8-EF08EC73E080Q33815701-A97DFCF8-22C2-4C00-8435-389C4C465064Q33895494-5BCDE1E3-EDF7-4427-B475-573FC8C22C9DQ33995471-3958F957-2926-4C1F-A24C-050FA0376739Q34048741-59F42756-D9EB-4213-B52B-E630936C6441Q34316241-CD45D30C-0790-4737-B242-4C69A3651BB5Q34388476-DDAD5DA4-3B59-4213-B8F8-8A80DDD20739Q34793516-D40EEB79-D2E5-4447-8EA4-8997D2AF0001Q34962518-46086F5B-BE4B-48CC-A6F3-DE210B1C2F98Q35058583-C177BE1E-7F1D-4176-9310-7195E8612381Q35275179-FC6B3982-10F8-4075-9AF5-A65DE6BA7597Q35591435-1E77A9A8-3DF3-49CB-BB59-087401E161AFQ35623101-80441D40-1854-42F1-8E38-D202E147B943Q35647212-84C475C1-491E-48AE-A876-225FFEB49573Q35783456-5918EB2D-4274-44A6-9BC3-EECEA57A387CQ36109704-CF710D2B-F2F3-4381-870D-16ED67EDB38DQ36226841-FB135C42-E93C-4334-9574-521AFDC253DAQ36261379-77AF5159-1B45-4896-B9BB-FDFA0B8FA5F8Q36278738-9B8D7668-865E-4616-8889-6C924037009CQ36456487-3969ED1D-FFA2-4884-8090-7178143FFF55Q36562901-41CD4D24-8D86-4979-97CE-7C941B29A179Q36659289-D2E852D9-7AE2-4E08-8EC0-1021B0B3DCF4Q36659325-2ADD24C1-5EB2-47F1-88A7-1A8AFFC46C80Q36750814-A238A6C7-4D79-48CC-ABF3-A8DAB80674EEQ36883833-D00B62E4-68FB-4F21-8F02-B1F11E40B215Q36904198-108C730E-02CE-4530-B687-491DA07D89D0Q37086063-BC0727F8-1FD7-4776-8FAF-5BABDB567110Q37198935-4BF12008-45BB-493F-B7D3-3250D24C51C4Q37225501-0A4E3E4C-0E96-4A71-B2D7-3FC0B5293762Q37256658-479057AB-AD74-4886-B825-347F1B0E16D9Q37386616-144925D9-C545-4C0A-AE6F-00E1B007138B
P2860
Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@ast
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@en
type
label
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@ast
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@en
prefLabel
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@ast
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@en
P2093
P2860
P1476
Oncolytic virotherapy: molecul ...... delivery of oncolytic viruses
@en
P2093
David L Bartlett
Stephen H Thorne
Z Sheng Guo
P2860
P304
P356
10.1016/J.BBCAN.2008.02.001
P407
P577
2008-02-15T00:00:00Z